Información del artículo
El Texto completo está disponible en PDF
Referencias bibliográficas
[1.]
Greenlee R.T., Murray T., Bolden S., et al.
Cancer Statistics.
Ca Cancer J Clin, 50 (2000), pp. 7-33
[2.]
Ferreiro J., Fernandez R., Rubio I., Abón G..
Indicaciones de Quimioterapia en el cáncer de mama.
Gac Med Bilbao, 97 (2000), pp. 105-114
[3.]
López Vivanco G., Viteri A., Pérez M.T., Fuente N..
Indicación de la hormonoterapia en cáncer de mama.
Gac Med Bilbao, 97 (2000), pp. 119-121
[4.]
Barceló JR, Mañié JM, Rubio I, et al. Tratamiento adyuvante del cáncer de mama. Tratamientos futuros de quimioterapia. Ann Oncol (ed esp) 2000. En prensa.
[5.]
Armstrong K., Eisen A., Weber B..
Primary care: Assessing the risk of Breast Cancer.
N Engl J Med, 342 (2000), pp. 564-571
[6.]
Osborne C.K..
Drug Therapy: Tamoxifen in the treatment of breast cancer.
N Engl J Med, 339 (1998), pp. 1609-1618
[7.]
Chlebowski R.T..
Primary care: Reducing the risk of breast cancer.
N Engl J Med, 343 (2000), pp. 191-198
[8.]
Jatoi A..
Loprinzi CL.
Nutritional determinants of survival among patients with breast cancer. Surg Clin North Am, 79 (1999), pp. 1145-1156
[9.]
Hartmann L.C., Schaid D.J., Woods J.E., et al.
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.
N Engl J Med, 340 (1999), pp. 77-84
[10.]
Burnstein H.J., Winer E.P..
Primary care: Primary care for survivors of breast cancer.
N Engl J Med, 343 (2000), pp. 1086-1094
[11.]
Breast Cancer Trialist's Collaborative Group.
Polichemotherapy for early breast cancer: An overview of the randomised trials.
Lancet, 352 (1998), pp. 930-942
[12.]
Henderson I., Berry D., Demetri G., et al.
Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (Pts) with node-positive primary breast cancer (BC).
Proc Am Soc Clin Oncol, 17 (1998), pp. 101a
[13.]
Fizazi K., Zelek L..
Is ‘one cycle every three or four weeks’ obsolete? A critical review of dose-dense chemotherapy in solid neoplasms.
Ann Oncol, 11 (2000), pp. 133-149
[14.]
McNamee D..
High-dose chemotherapy positive in breast-cancer trial.
Lancet, 355 (2000), pp. 1978
[15.]
Bonadonna G., Valagussa P., Brambilla C., Ferrari L., Moliterni A., Terenziani M., Zambetti M..
Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.
J Clin Oncol, 16 (1998), pp. 93-100
[16.]
Vogel C.L., Nabholtz J-M.
Monotherapy of metastatic breast cancer: A review of newer drugs.
Oncologist, 4 (1999), pp. 17-33
[17.]
Peters W., Dansey R.D., Klein J.L., et al.
High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer.
Oncologist, 5 (2000), pp. 1-13
[18.]
Osborne C.K., Zhao H., Fuqua S.A..
Selective estrogen receptor modulators: structure, function, and clinical use.
J Clin Oncol, 18 (2000), pp. 3172-3186
[19.]
Nabohltz J.M., Buzdar A., Pollak M., et al.
Anastrozol is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a north american multicenter randomized trial.
J Clin Oncol, 18 (2000), pp. 3758-3767
[20.]
Pritchard K.I..
Current and future directions in medical therapy for breast carcinoma: endocrine treatment.
Cancer, 88 (2000), pp. 3065-3072
[21.]
Badwe R.A., Mittra I., Havaldar R..
Timing of surgery with regard to the menstrual cycle in women with primary breast cancer.
Surg Clin North Am, 79 (1999), pp. 1047-1059
[22.]
Von Hoff D.D..
New agents with new mechanisms of action and clinical activity, ASCO Fall Educational Conference Book, (1999),
[23.]
Folkman J..
Clinical applications of research on angiogenesis.
N Engl J Med, 333 (1995), pp. 1757-1763
[24.]
Fentiman I.S..
Future prospects for the prevention and cure of breast cancer.
Eur J Cancer, 36 (2000), pp. 1085-1088
[25.]
http://cancertrials.nci.nih.gov/, revisado diciembre 2000.
[26.]
Childs R., Chernoff A., Contentin N., et al.
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheralblood stem-cell transplantation.
N Engl J Med, 343 (2000), pp. 750-758
Copyright © 2001. Academia de Ciencias Médicas de Bilbao